DR
₹1,368.30
+26.30(+1.96%)
DRREDDY₹1,368.30+1.96%
Group Companies
Foreign Flows
sector level — not this stockHealthcare sector+₹3 Crnet foreign buying
2026-09-16 to 2026-09-endThis is the flow into the whole Healthcare sector, not into DRREDDY. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.
Supply Chain
suppliers and customers in the graphMacro Sensitivity
rates, currency, commoditiesRevenue by Segment
Business Group
Geographic Exposure
revenue, imports, currencyScenario analysis
stated assumptions, shown workingsDRREDDY exposure summary
In its latest segment disclosure (Sep 2026), a) Global Generics was the largest segment at 87.5% of segment revenue, followed by b) Pharmaceutical Services and Active Ingredients at 11.9%. Dr. Reddy's Laboratories Limited is a constituent of 11 indices, with its largest weights in NIFTY Pharma (7.63%), NIFTY Healthcare Index (6.84%), NIFTY India Manufacturing (1.58%). 28 exchange-traded funds hold the stock.
| Index memberships | 11 |
|---|---|
| ETFs holding | 28 |
| Largest segment | a) Global Generics · 87.5% |